The Latest Cardiac and Vascular News
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures DANVERS, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — Abiomed(Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an […]
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed(NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women’s Initiative focused on heart recovery education and awareness. This Women’s Initiative is […]
DANVERS, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) — Abiomed(NASDAQ:ABMD) announced that on Thursday, February 1, 2018, the Company will release financial results for the third quarter of fiscal 2018. The Company will host a conference call to discuss the results on […]
Maquet files new patent infringement dispute based on a patent from earlier this year Maquet opens a new front in patent war with Abiomed NOVEMBER 28, 2017 BY BRAD PERRIELLO, MassDevice Getinge (PINK:GETI B) subsidiary Maquet opened a new front last week in its patent […]
DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30 presentations potentially featuring the Impella® line of heart pumps scheduled during the 29th […]
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company will host a conference call to discuss the […]
TEL-AVIV, Israel, September 28, 2017 /PRNewswire/ — Magenta Medical, a medical device company in the field of transcatheter heart failure therapy, announced today the successful closing of its $15M series B financing round. The syndicate of investors is comprised of Abiomed Inc., a leader […]
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. […]
DANVERS, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017. After two […]
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 […]
